No profile data available.
Protalix BioTherapeutics, Inc. (PLX) is a healthcare company in the metabolic process treatment drugs industry, based in Hackensack, United States, with about 213 full-time employees.
It reported revenue of $52.74 million for fiscal year 2025, down 1.2% from fiscal year 2024, and net income of -$6.60 million. Its market capitalization was $140.74 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Protalix BioTherapeutics reported $52.74 million in revenue for fiscal year 2025, down 1.2% from $53.40 million in fiscal year 2024.
$140.74 million as of December 4, 2025.
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include Amarin Corporation plc (AMRN), Cartesian Therapeutics, Inc. (RNAC), Camp4 Therapeutics Corp (CAMP), Xortx Therapeutics Inc. (XRTX).